Cargando…

The soluble mannose receptor (sMR/sCD206) in critically ill patients with invasive fungal infections, bacterial infections or non-infectious inflammation: a secondary analysis of the EPaNIC RCT

BACKGROUND: Invasive fungal infections (IFI) are difficult to diagnose, especially in critically ill patients. As the mannose receptor (MR) is shed from macrophage cell surfaces after exposure to fungi, we investigate whether its soluble serum form (sMR) can serve as a biomarker of IFI. METHODS: Thi...

Descripción completa

Detalles Bibliográficos
Autores principales: De Vlieger, Greet, Vanhorebeek, Ilse, Wouters, Pieter J., Derese, Inge, Casaer, Michael P., Debaveye, Yves, Hermans, Greet, Meersseman, Philippe, Møller, Holger J., Van den Berghe, Greet, Ingels, Catherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6679534/
https://www.ncbi.nlm.nih.gov/pubmed/31375142
http://dx.doi.org/10.1186/s13054-019-2549-8
_version_ 1783441357491142656
author De Vlieger, Greet
Vanhorebeek, Ilse
Wouters, Pieter J.
Derese, Inge
Casaer, Michael P.
Debaveye, Yves
Hermans, Greet
Meersseman, Philippe
Møller, Holger J.
Van den Berghe, Greet
Ingels, Catherine
author_facet De Vlieger, Greet
Vanhorebeek, Ilse
Wouters, Pieter J.
Derese, Inge
Casaer, Michael P.
Debaveye, Yves
Hermans, Greet
Meersseman, Philippe
Møller, Holger J.
Van den Berghe, Greet
Ingels, Catherine
author_sort De Vlieger, Greet
collection PubMed
description BACKGROUND: Invasive fungal infections (IFI) are difficult to diagnose, especially in critically ill patients. As the mannose receptor (MR) is shed from macrophage cell surfaces after exposure to fungi, we investigate whether its soluble serum form (sMR) can serve as a biomarker of IFI. METHODS: This is a secondary analysis of the multicentre randomised controlled trial (EPaNIC, n = 4640) that investigated the impact of initiating supplemental parenteral nutrition (PN) early during critical illness (Early-PN) as compared to withholding it in the first week of intensive care (Late-PN). Serum sMR concentrations were measured in three matched patient groups (proven/probable IFI, n = 82; bacterial infection, n = 80; non-infectious inflammation, n = 77) on the day of antimicrobial initiation or matched intensive care unit day and the five preceding days, as well as in matched healthy controls (n = 59). Independent determinants of sMR concentration were identified via multivariable linear regression. Serum sMR time profiles were analysed with repeated-measures ANOVA. Predictive properties were assessed via area under the receiver operating curve (aROC). RESULTS: Serum sMR was higher in IFI patients than in all other groups (all p < 0.02), aROC to differentiate IFI from no IFI being 0.65 (p < 0.001). The ability of serum sMR to discriminate infectious from non-infectious inflammation was better with an aROC of 0.68 (p < 0.001). The sMR concentrations were already elevated up to 5 days before antimicrobial initiation and remained stable over time. Multivariable linear regression analysis showed that an infection or an IFI, higher severity of illness and sepsis upon admission were associated with higher sMR levels; urgent admission and Late-PN were independently associated with lower sMR concentrations. CONCLUSION: Serum sMR concentrations were higher in critically ill patients with IFI than in those with a bacterial infection or with non-infectious inflammation. However, test properties were insufficient for diagnostic purposes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13054-019-2549-8) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6679534
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-66795342019-08-06 The soluble mannose receptor (sMR/sCD206) in critically ill patients with invasive fungal infections, bacterial infections or non-infectious inflammation: a secondary analysis of the EPaNIC RCT De Vlieger, Greet Vanhorebeek, Ilse Wouters, Pieter J. Derese, Inge Casaer, Michael P. Debaveye, Yves Hermans, Greet Meersseman, Philippe Møller, Holger J. Van den Berghe, Greet Ingels, Catherine Crit Care Research BACKGROUND: Invasive fungal infections (IFI) are difficult to diagnose, especially in critically ill patients. As the mannose receptor (MR) is shed from macrophage cell surfaces after exposure to fungi, we investigate whether its soluble serum form (sMR) can serve as a biomarker of IFI. METHODS: This is a secondary analysis of the multicentre randomised controlled trial (EPaNIC, n = 4640) that investigated the impact of initiating supplemental parenteral nutrition (PN) early during critical illness (Early-PN) as compared to withholding it in the first week of intensive care (Late-PN). Serum sMR concentrations were measured in three matched patient groups (proven/probable IFI, n = 82; bacterial infection, n = 80; non-infectious inflammation, n = 77) on the day of antimicrobial initiation or matched intensive care unit day and the five preceding days, as well as in matched healthy controls (n = 59). Independent determinants of sMR concentration were identified via multivariable linear regression. Serum sMR time profiles were analysed with repeated-measures ANOVA. Predictive properties were assessed via area under the receiver operating curve (aROC). RESULTS: Serum sMR was higher in IFI patients than in all other groups (all p < 0.02), aROC to differentiate IFI from no IFI being 0.65 (p < 0.001). The ability of serum sMR to discriminate infectious from non-infectious inflammation was better with an aROC of 0.68 (p < 0.001). The sMR concentrations were already elevated up to 5 days before antimicrobial initiation and remained stable over time. Multivariable linear regression analysis showed that an infection or an IFI, higher severity of illness and sepsis upon admission were associated with higher sMR levels; urgent admission and Late-PN were independently associated with lower sMR concentrations. CONCLUSION: Serum sMR concentrations were higher in critically ill patients with IFI than in those with a bacterial infection or with non-infectious inflammation. However, test properties were insufficient for diagnostic purposes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13054-019-2549-8) contains supplementary material, which is available to authorized users. BioMed Central 2019-08-02 /pmc/articles/PMC6679534/ /pubmed/31375142 http://dx.doi.org/10.1186/s13054-019-2549-8 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
De Vlieger, Greet
Vanhorebeek, Ilse
Wouters, Pieter J.
Derese, Inge
Casaer, Michael P.
Debaveye, Yves
Hermans, Greet
Meersseman, Philippe
Møller, Holger J.
Van den Berghe, Greet
Ingels, Catherine
The soluble mannose receptor (sMR/sCD206) in critically ill patients with invasive fungal infections, bacterial infections or non-infectious inflammation: a secondary analysis of the EPaNIC RCT
title The soluble mannose receptor (sMR/sCD206) in critically ill patients with invasive fungal infections, bacterial infections or non-infectious inflammation: a secondary analysis of the EPaNIC RCT
title_full The soluble mannose receptor (sMR/sCD206) in critically ill patients with invasive fungal infections, bacterial infections or non-infectious inflammation: a secondary analysis of the EPaNIC RCT
title_fullStr The soluble mannose receptor (sMR/sCD206) in critically ill patients with invasive fungal infections, bacterial infections or non-infectious inflammation: a secondary analysis of the EPaNIC RCT
title_full_unstemmed The soluble mannose receptor (sMR/sCD206) in critically ill patients with invasive fungal infections, bacterial infections or non-infectious inflammation: a secondary analysis of the EPaNIC RCT
title_short The soluble mannose receptor (sMR/sCD206) in critically ill patients with invasive fungal infections, bacterial infections or non-infectious inflammation: a secondary analysis of the EPaNIC RCT
title_sort soluble mannose receptor (smr/scd206) in critically ill patients with invasive fungal infections, bacterial infections or non-infectious inflammation: a secondary analysis of the epanic rct
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6679534/
https://www.ncbi.nlm.nih.gov/pubmed/31375142
http://dx.doi.org/10.1186/s13054-019-2549-8
work_keys_str_mv AT devliegergreet thesolublemannosereceptorsmrscd206incriticallyillpatientswithinvasivefungalinfectionsbacterialinfectionsornoninfectiousinflammationasecondaryanalysisoftheepanicrct
AT vanhorebeekilse thesolublemannosereceptorsmrscd206incriticallyillpatientswithinvasivefungalinfectionsbacterialinfectionsornoninfectiousinflammationasecondaryanalysisoftheepanicrct
AT wouterspieterj thesolublemannosereceptorsmrscd206incriticallyillpatientswithinvasivefungalinfectionsbacterialinfectionsornoninfectiousinflammationasecondaryanalysisoftheepanicrct
AT dereseinge thesolublemannosereceptorsmrscd206incriticallyillpatientswithinvasivefungalinfectionsbacterialinfectionsornoninfectiousinflammationasecondaryanalysisoftheepanicrct
AT casaermichaelp thesolublemannosereceptorsmrscd206incriticallyillpatientswithinvasivefungalinfectionsbacterialinfectionsornoninfectiousinflammationasecondaryanalysisoftheepanicrct
AT debaveyeyves thesolublemannosereceptorsmrscd206incriticallyillpatientswithinvasivefungalinfectionsbacterialinfectionsornoninfectiousinflammationasecondaryanalysisoftheepanicrct
AT hermansgreet thesolublemannosereceptorsmrscd206incriticallyillpatientswithinvasivefungalinfectionsbacterialinfectionsornoninfectiousinflammationasecondaryanalysisoftheepanicrct
AT meerssemanphilippe thesolublemannosereceptorsmrscd206incriticallyillpatientswithinvasivefungalinfectionsbacterialinfectionsornoninfectiousinflammationasecondaryanalysisoftheepanicrct
AT møllerholgerj thesolublemannosereceptorsmrscd206incriticallyillpatientswithinvasivefungalinfectionsbacterialinfectionsornoninfectiousinflammationasecondaryanalysisoftheepanicrct
AT vandenberghegreet thesolublemannosereceptorsmrscd206incriticallyillpatientswithinvasivefungalinfectionsbacterialinfectionsornoninfectiousinflammationasecondaryanalysisoftheepanicrct
AT ingelscatherine thesolublemannosereceptorsmrscd206incriticallyillpatientswithinvasivefungalinfectionsbacterialinfectionsornoninfectiousinflammationasecondaryanalysisoftheepanicrct
AT devliegergreet solublemannosereceptorsmrscd206incriticallyillpatientswithinvasivefungalinfectionsbacterialinfectionsornoninfectiousinflammationasecondaryanalysisoftheepanicrct
AT vanhorebeekilse solublemannosereceptorsmrscd206incriticallyillpatientswithinvasivefungalinfectionsbacterialinfectionsornoninfectiousinflammationasecondaryanalysisoftheepanicrct
AT wouterspieterj solublemannosereceptorsmrscd206incriticallyillpatientswithinvasivefungalinfectionsbacterialinfectionsornoninfectiousinflammationasecondaryanalysisoftheepanicrct
AT dereseinge solublemannosereceptorsmrscd206incriticallyillpatientswithinvasivefungalinfectionsbacterialinfectionsornoninfectiousinflammationasecondaryanalysisoftheepanicrct
AT casaermichaelp solublemannosereceptorsmrscd206incriticallyillpatientswithinvasivefungalinfectionsbacterialinfectionsornoninfectiousinflammationasecondaryanalysisoftheepanicrct
AT debaveyeyves solublemannosereceptorsmrscd206incriticallyillpatientswithinvasivefungalinfectionsbacterialinfectionsornoninfectiousinflammationasecondaryanalysisoftheepanicrct
AT hermansgreet solublemannosereceptorsmrscd206incriticallyillpatientswithinvasivefungalinfectionsbacterialinfectionsornoninfectiousinflammationasecondaryanalysisoftheepanicrct
AT meerssemanphilippe solublemannosereceptorsmrscd206incriticallyillpatientswithinvasivefungalinfectionsbacterialinfectionsornoninfectiousinflammationasecondaryanalysisoftheepanicrct
AT møllerholgerj solublemannosereceptorsmrscd206incriticallyillpatientswithinvasivefungalinfectionsbacterialinfectionsornoninfectiousinflammationasecondaryanalysisoftheepanicrct
AT vandenberghegreet solublemannosereceptorsmrscd206incriticallyillpatientswithinvasivefungalinfectionsbacterialinfectionsornoninfectiousinflammationasecondaryanalysisoftheepanicrct
AT ingelscatherine solublemannosereceptorsmrscd206incriticallyillpatientswithinvasivefungalinfectionsbacterialinfectionsornoninfectiousinflammationasecondaryanalysisoftheepanicrct